FDA Clearance Tracker · P150031-S064
Vercise PC DBS System, Vercise Gervia DBS System, Vercise Genus DBS System
Last checked: Nov 20, 2026Latest source record: Feb 29, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Feb 29, 2024
Approved
Time to decision
153 days
Received Sep 29, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150031-S064
- Device name
- Vercise PC DBS System, Vercise Gervia DBS System, Vercise Genus DBS System
- Applicant
- Boston Scientific Corp
- Applicant location
- Valencia, CA
- Received
- Sep 29, 2023
- Decided
- Feb 29, 2024
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150031
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Expanding the current indications for use (IFU) to include Bilateral stimulation of the ventral intermediate nucleus (VIM) of the thalamus for the suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and where the tremor constitutes a significant functional disability
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.